Double-oughtober, Robin. Hopefully, more permanent than the one day we had of March Gladness.
But if our Covid-expedited rolling review is designed to shorten the UK's 60 - 100 day normal response time, it's feasible that we could get market authorization next month, especially if NICE is nice.
And with data on additional patients, as well as more data on our trial patients, peer-reviewed, I could see the FDA reverse their decline next month, and grant either an EUA or a full approval. The data was just that good.
I could use greener...everything. I join you in hoping that it's soon, and thank you!